David R. Walt Acquires 123,990 Shares of Quanterix Co. (NASDAQ:QTRX) Stock

Quanterix Co. (NASDAQ:QTRX - Get Free Report) Director David R. Walt purchased 123,990 shares of the business's stock in a transaction on Friday, June 13th. The shares were acquired at an average price of $6.14 per share, with a total value of $761,298.60. Following the purchase, the director now owns 1,866,933 shares of the company's stock, valued at approximately $11,462,968.62. This trade represents a 7.11% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Quanterix Price Performance

Shares of QTRX traded down $0.13 on Friday, hitting $6.06. The company's stock had a trading volume of 567,189 shares, compared to its average volume of 591,459. The company has a market capitalization of $235.30 million, a PE ratio of -5.72 and a beta of 1.05. Quanterix Co. has a fifty-two week low of $4.05 and a fifty-two week high of $18.02. The company has a 50 day moving average price of $5.32 and a 200 day moving average price of $7.81.

Quanterix (NASDAQ:QTRX - Get Free Report) last issued its quarterly earnings data on Monday, May 12th. The company reported ($0.53) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.69) by $0.16. The firm had revenue of $30.33 million during the quarter, compared to the consensus estimate of $28.27 million. Quanterix had a negative return on equity of 11.74% and a negative net margin of 30.12%. On average, equities analysts forecast that Quanterix Co. will post -0.98 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Bank of New York Mellon Corp grew its holdings in Quanterix by 1.8% during the 4th quarter. Bank of New York Mellon Corp now owns 108,186 shares of the company's stock worth $1,150,000 after acquiring an additional 1,963 shares during the last quarter. Jane Street Group LLC lifted its position in shares of Quanterix by 4.2% during the first quarter. Jane Street Group LLC now owns 58,313 shares of the company's stock worth $380,000 after purchasing an additional 2,366 shares in the last quarter. Tower Research Capital LLC TRC raised its position in Quanterix by 219.1% in the 4th quarter. Tower Research Capital LLC TRC now owns 5,702 shares of the company's stock worth $61,000 after purchasing an additional 3,915 shares during the last quarter. Hsbc Holdings PLC boosted its holdings in Quanterix by 25.8% in the fourth quarter. Hsbc Holdings PLC now owns 19,371 shares of the company's stock valued at $205,000 after acquiring an additional 3,974 shares during the last quarter. Finally, Canada Pension Plan Investment Board boosted its stake in shares of Quanterix by 64.5% in the 4th quarter. Canada Pension Plan Investment Board now owns 10,200 shares of the company's stock valued at $108,000 after purchasing an additional 4,000 shares during the last quarter. 86.48% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several research firms have recently weighed in on QTRX. Leerink Partnrs lowered Quanterix from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, April 30th. Canaccord Genuity Group decreased their price target on Quanterix from $15.00 to $12.00 and set a "buy" rating on the stock in a research note on Tuesday, May 13th. Scotiabank reiterated an "outperform" rating on shares of Quanterix in a research note on Tuesday, March 25th. Wall Street Zen cut Quanterix from a "hold" rating to a "sell" rating in a report on Thursday, May 22nd. Finally, Leerink Partners restated a "market perform" rating and issued a $8.00 target price (down previously from $12.00) on shares of Quanterix in a research note on Wednesday, April 30th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and an average price target of $15.60.

About Quanterix

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.